Jingyun Ji

Title: The Innovative Contributions of Jingyun Ji in Biotechnology

Introduction

Jingyun Ji is a notable inventor based in Guangdong, China, particularly recognized for his work in the field of biotechnology. With a focus on developing advanced systems for scientific applications, he has made significant strides that contribute to our understanding of viral responses. His inventive spirit and dedication have led to the development of groundbreaking technologies.

Latest Patents

Jingyun Ji holds a patent for a "Lentiviral vector capable of directly reflecting type I interferon response, preparation method thereof, and applications thereof." This innovative patent outlines a method for establishing a lentiviral vector system that can directly reflect the type I interferon response. The establishment of this system involves cutting luciferase at the position of amino acid 109, removing 16 amino acids from the N-terminus, and cloning two polypeptides into a lentiviral vector to create a lentiviral BiLC expression vector. Furthermore, the inclusion of a shuttle plasmid via homologous recombination enhances its functionality, allowing for the construction of lentiviral vectors capable of directly reflecting the type I interferon response.

Career Highlights

Currently, Jingyun Ji is associated with Fantasia Biopharma (Zhejiang) Co. Ltd., a company that emphasizes innovation in biopharmaceuticals. His work contributes to the larger body of research dedicated to understanding infectious diseases and developing treatments that can improve patient outcomes.

Collaborations

During his career, Jingyun Ji has collaborated with talented colleagues, including Frank XiaoFeng Qin and Fei Wu. These partnerships have facilitated the sharing of ideas and advancements in research, further propelling their respective contributions to the field of biotechnology.

Conclusion

Jingyun Ji's innovative spirit and his patent for a novel lentiviral vector highlight the pivotal role of inventors in advancing biotechnology. Through his work at Fantasia Biopharma, he continues to push the boundaries of what is possible in understanding viral interactions, ultimately aiding the scientific community in developing effective therapeutic strategies.